A boost with SARS-CoV-2 BNT162b2 mRNA vaccine elicits strong humoral responses independently of the interval between the first two doses.
COVID-19
CP: Immunology
SARS-CoV-2
coronavirus
humoral responses
long interval
spike glycoproteins
third mRNA vaccine dose
variants of concern
Journal
Cell reports
ISSN: 2211-1247
Titre abrégé: Cell Rep
Pays: United States
ID NLM: 101573691
Informations de publication
Date de publication:
25 10 2022
25 10 2022
Historique:
received:
18
04
2022
revised:
27
07
2022
accepted:
03
10
2022
pubmed:
17
10
2022
medline:
29
10
2022
entrez:
16
10
2022
Statut:
ppublish
Résumé
Due to the recrudescence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections worldwide, mainly caused by the Omicron variant of concern (VOC) and its sub-lineages, several jurisdictions are administering an mRNA vaccine boost. Here, we analyze humoral responses induced after the second and third doses of an mRNA vaccine in naive and previously infected donors who received their second dose with an extended 16-week interval. We observe that the extended interval elicits robust humoral responses against VOCs, but this response is significantly diminished 4 months after the second dose. Administering a boost to these individuals brings back the humoral responses to the same levels obtained after the extended second dose. Interestingly, we observe that administering a boost to individuals that initially received a short 3- to 4-week regimen elicits humoral responses similar to those observed in the long interval regimen. Nevertheless, humoral responses elicited by the boost in naive individuals do not reach those present in previously infected vaccinated individuals.
Identifiants
pubmed: 36244343
pii: S2211-1247(22)01410-3
doi: 10.1016/j.celrep.2022.111554
pmc: PMC9533674
pii:
doi:
Substances chimiques
BNT162 Vaccine
0
Antibodies, Viral
0
Viral Vaccines
0
COVID-19 Vaccines
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
111554Subventions
Organisme : NIAID NIH HHS
ID : U19 AI082630
Pays : United States
Organisme : CIHR
ID : 352417
Pays : Canada
Organisme : CIHR
ID : 177958
Pays : Canada
Organisme : CIHR
ID : OV3 170632
Pays : Canada
Informations de copyright
Copyright © 2022 The Author(s). Published by Elsevier Inc. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of interests A.R.G. is a consultant for Relation Therapeutics. E.J.W. is consulting for or is an advisor for Merck, Marengo, Janssen, Related Sciences, Synthekine, and Surface Oncology. E.J.W. is a founder of Surface Oncology, Danger Bio, and Arsenal Biosciences.
Références
Nat Med. 2022 Mar;28(3):477-480
pubmed: 35046572
JAMA. 2022 Feb 15;327(7):639-651
pubmed: 35060999
Transfusion. 2021 May;61(5):1377-1382
pubmed: 33604922
Viruses. 2022 Mar 04;14(3):
pubmed: 35336940
MMWR Morb Mortal Wkly Rep. 2022 Feb 18;71(7):255-263
pubmed: 35176007
Cell Rep. 2022 Jun 28;39(13):111013
pubmed: 35732172
Int J Surg. 2022 Jul;103:106698
pubmed: 35690362
N Engl J Med. 2022 Apr 21;386(16):1532-1546
pubmed: 35249272
J Clin Lab Anal. 2017 Nov;31(6):
pubmed: 28124796
Yonsei Med J. 2021 Nov;62(11):961-968
pubmed: 34672129
Med (N Y). 2022 Apr 8;3(4):249-261.e4
pubmed: 35261995
Cell Rep Med. 2020 Oct 20;1(7):100126
pubmed: 33015650
Cell Rep. 2021 Jul 13;36(2):109353
pubmed: 34237283
Cell Rep. 2022 Mar 1;38(9):110429
pubmed: 35216664
Immunity. 2021 Sep 14;54(9):2143-2158.e15
pubmed: 34453881
Sci Immunol. 2021 Apr 15;6(58):
pubmed: 33858945
MMWR Morb Mortal Wkly Rep. 2022 Jan 21;71(4):139-145
pubmed: 35085224
J Chem Inf Model. 2022 Jan 24;62(2):412-422
pubmed: 34989238
Nature. 2022 Mar;603(7902):679-686
pubmed: 35042229
J Med Virol. 2022 Oct;94(10):4780-4791
pubmed: 35680610
Virology. 2021 Nov;563:134-145
pubmed: 34536797
Cell Rep. 2022 Jan 11;38(2):110210
pubmed: 34971573
STAR Protoc. 2021 Dec 17;2(4):100851
pubmed: 34541555
N Engl J Med. 2022 Feb 3;386(5):492-494
pubmed: 34965337
N Engl J Med. 2022 Mar 17;386(11):1088-1091
pubmed: 35081298
J Vet Diagn Invest. 1999 Jan;11(1):41-4
pubmed: 9925210
PLoS Med. 2006 Jul;3(7):e237
pubmed: 16796401
Cell. 2021 Nov 11;184(23):5699-5714.e11
pubmed: 34735795
mBio. 2020 Oct 16;11(5):
pubmed: 33067385
Immunity. 2021 Aug 10;54(8):1652-1664
pubmed: 34380063
N Engl J Med. 2022 Feb 10;386(6):599-601
pubmed: 35030645
Cell Host Microbe. 2022 Jan 12;30(1):97-109.e5
pubmed: 34953513
Cell Rep Med. 2021 Jun 15;2(6):100290
pubmed: 33969322
Science. 2021 Nov 19;374(6570):995-999
pubmed: 34648303
Nature. 2021 Dec;600(7889):530-535
pubmed: 34670266
Cell Host Microbe. 2021 Jul 14;29(7):1137-1150.e6
pubmed: 34133950